Results for this period
First quarter1 July 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Steady sales of equipment for genetic testing and an increase in cumulative shipments drove growth in sales of nucleic acid extraction reagents and related consumables. Revenue from contract development declined, while personnel and logistics costs increased.
No applicable items
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2026–30 September 2026 |
| Net Sales | ¥1,488 million (YoY +13.0%) |
| Operating profit | ¥160 million (YoY +187.2%) |
| Ordinary income | ¥133 million (YoY +128.4%) |
| Profit attributable to owners of the parent | ¥126 million (YoY +132.8%) |
| Net income per share | ¥4.61 |
| Equity ratio | End of the current fiscal period 70.8 / End of previous period 69.9 |
| Total assets | ¥5,874 million |
| Net assets | ¥4,157 million |
| Full-year earnings forecast | Net Sales ¥5,650 million (YoY +8.3%) / Operating profit ¥350 million (YoY +73.9%) / Ordinary income ¥298 million (YoY +91.3%) / Profit attributable to owners of the parent ¥292 million (YoY -26.0%) |
| Annual Dividend Forecast | ¥2 → ¥3（+50.0%） |
| Depreciation and amortization | ¥44,475 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on disposal of fixed assets ¥31 thousand |
| Disclosure regarding the going concern assumption | No applicable items |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 27,666,900 Shares |
| Treasury Shares at Period-End | 206,170 Shares |
| Factors Behind Changes in Business Performance | Steady sales of equipment for genetic testing and an increase in cumulative shipments drove growth in sales of nucleic acid extraction reagents and related consumables. Revenue from contract development declined, while personnel and logistics costs increased. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Steady sales of equipment for genetic testing and an increase in cumulative shipments drove growth in sales of nucleic acid extraction reagents and related consumables. The company also strengthened transactions with existing customers and expanded sales, maintained a stable product supply, and strengthened its quality control system. Meanwhile, personnel and logistics costs increased.